Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease

Clinics in Liver Disease

Volumn 8, Issue 3, 2004, Pages 575-594

  Choudhury, Jayanta ^a   Sanyal, Arun J ^a,b  

^a Division of Gastroenterology   (United States)

^b VA 23298 0711 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR;

CARBOHYDRATE METABOLISM; EVIDENCE BASED MEDICINE; HORMONE ACTION; HUMAN; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION;

CARBOHYDRATE METABOLISM; FATTY ACIDS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 4344628553     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.04.006     Document Type: Review

References (100)

1. Kuczmarski R.J., Carroll M.D., Flegal K.M., Troiano R.P. Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III (1988 to 1994). Obes Res. 5(6):1997;542-548
2. Pi-Sunyer F.X. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 10(Suppl 2):2002;97S-104S
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285(19):2001;2486-2497
4. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288(21):2002;2709-2716
5. Kekalainen P., Sarlund H., Laakso M. Long-term association of cardiovascular risk factors with impaired insulin secretion and insulin resistance. Metabolism. 49(10):2000;1247-1254
6. Kekalainen P., Sarlund H., Pyorala K., Laakso M. Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. Diabetes Care. 22(1):1999;86-92
7. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55(7):1980;434-438
8. Fusamoto H., Suzuki K., Hayashi N., Sasaki Y., Kono M., Kasahara A., et al. Obesity and liver disease: evaluation of fatty infiltration of the liver using ultrasonic attenuation. J Nutr Sci Vitaminol (Tokyo). 37(Suppl):1991;S71- S77
9. Caturelli E., Squillante M.M., Andriulli A., Cedrone A., Cellerino C., Pompili M., et al. Hypoechoic lesions in the 'bright liver': a reliable indicator of fatty change. A prospective study. J Gastroenterol Hepatol. 7(5):1992;469-472
10. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 12(5):1990;1106-1110
11. Underwood Ground K.E. Prevalence of fatty liver in healthy male adults accidentally killed. Aviat Space Environ Med. 55(1):1984;59-61
12. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 123(5):2002;1705-1725
13. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120(5):2001;1183-1192
14. Laakso M., Sarlund H., Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis. 10(2):1990;223-231
15. Du K., Herzig S., Kulkarni R.N., Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science. 300(5625):2003;1574-1577
16. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15(7):1998;539-553
17. Marceau P., Biron S., Hould F.S., Marceau S., Simard S., Thung S.N., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 84(5):1999;1513-1517
18. Garg A. Lipodystrophies. Am J Med. 108(2):2000;143-152
19. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 35(2):2002;367-372
20. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 107(5):1999;450-455
21. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237(3):1979;E214-E223
22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28(7):1985;412-419
23. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 85(7):2000;2402-2410
24. Olefsky J., Farquhar J.W., Reaven G. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes. 22(7):1973;507-513
25. Bergman R.N., Ider Y.Z., Bowden C.R., Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 236(6):1979;E667-E677
26. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 22(9):1999;1462-1470
27. Galvin P., Ward G., Walters J., Pestell R., Koschmann M., Vaag A., et al. A simple method for quantitation of insulin sensitivity and insulin release from an intravenous glucose tolerance test. Diabet Med. 9(10):1992;921-928
28. Patti M.E., Kahn C.R. The insulin receptor - a critical link in glucose homeostasis and insulin action. J Basic Clin Physiol Pharmacol. 9(2-4):1998;89-109
29. Kahn C.R., Baird K.L., Jarrett D.B., Flier J.S. Direct demonstration that receptor crosslinking or aggregation is important in insulin action. Proc Natl Acad Sci USA. 75(9):1978;4209-4213
30. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414(6865):2001;799-806
31. Nakae J., Accili D. The mechanism of insulin action. J Pediatr Endocrinol Metab. 12(Suppl 3):1999;721-731
32. Pessin J.E., Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 106(2):2000;165-169
33. Standaert M.L., Galloway L., Karnam P., Bandyopadhyay G., Moscat J., Farese R.V. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem. 272(48):1997;30075-30082
34. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol. 7(4):1997;261-269
35. Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejewska E., Morgenbesser S.D., et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 65(4):1991;663-675
36. Baumann C.A., Ribon V., Kanzaki M., Thurmond D.C., Mora S., Shigematsu S., et al. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature. 407(6801):2000;202-207
37. Chiang S.H., Baumann C.A., Kanzaki M., Thurmond D.C., Watson R.T., Neudauer C.L., et al. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature. 410(6831):2001;944-948
38. Watson R.T., Shigematsu S., Chiang S.H., Mora S., Kanzaki M., Macara I.G., et al. Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation. J Cell Biol. 154(4):2001;829-840
39. Zhang M., Chiang J.Y. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem. 276(45):2001;41690-41699
40. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 40(6):2001;439-452
41. Kahn B.B., Flier J.S. Obesity and insulin resistance. J Clin Invest. 106(4):2000;473-481
42. Nakae J., Park B.C., Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem. 274(23):1999;15982-15985
43. Shimomura I., Matsuda M., Hammer R.E., Bashmakov Y., Brown M.S., Goldstein J.L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 6(1):2000;77-86
44. Goldstein B.J., Li P.M., Ding W., Ahmad F., Zhang W.R. Regulation of insulin action by protein tyrosine phosphatases. Vitam Horm. 54:1998;67-96
45. Anthonsen M.W., Ronnstrand L., Wernstedt C., Degerman E., Holm C. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem. 273(1):1998;215-221
46. Newgard C.B., Brady M.J., O'Doherty R.M., Saltiel A.R. Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes. 49(12):2000;1967-1977
47. Brady M.J., Nairn A.C., Saltiel A.R. The regulation of glycogen synthase by protein phosphatase 1 in 3T3-L1 adipocytes. Evidence for a potential role for DARPP-32 in insulin action. J Biol Chem. 272(47):1997;29698-29703
48. Pilkis S.J., Granner D.K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 54:1992;885-909
49. Beale E.G., Koch S.R., Brotherton A.F., Sheorain V.S., Granner D.K. Insulin decreases H4IIE cell PEPCK mRNA by a mechanism that does not involve cAMP. Diabetes. 35(5):1986;546-549
50. Reddy J.K. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 281(6):2001;G1333-G1339
51. Pessayre D., Berson A., Fromenty B., Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis. 21(1):2001;57-69
52. Prentki M., Corkey B.E. Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes. 45(3):1996;273-283
53. Randle P.J., Priestman D.A., Mistry S., Halsall A. Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia. 37(Suppl 2):1994;S155-S161
54. Gulick T., Cresci S., Caira T., Moore D.D., Kelly D.P. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA. 91(23):1994;11012-11016
55. Flier J.S. Lilly Lecture: syndromes of insulin resistance. From patient to gene and back again. Diabetes. 41(9):1992;1207-1219
56. Klein J., Fasshauer M., Ito M., Lowell B.B., Benito M., Kahn C.R. Beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem. 274(49):1999;34795-34802
57. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord. 20(4):1996;291-302
58. Hube F., Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res. 31(12):1999;626-631
59. Harris R.B. Leptin - much more than a satiety signal. Annu Rev Nutr. 20:2000;45-75
60. Diez J.J., Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 148(3):2003;293-300
61. Goodpaster B.H., Thaete F.L., Simoneau J.A., Kelley D.E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 46(10):1997;1579-1585
62. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37(12):1988;1595-1607
63. Swislocki A.L., Chen Y.D., Golay A., Chang M.O., Reaven G.M. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia. 30(8):1987;622-626
64. Tomlinson J.W., Stewart P.M. Cortisol metabolism and the role of 11 beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab. 15(1):2001;61-78
65. Tomlinson J.W., Bujalska I., Stewart P.M., Cooper M.S. The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res. 26(4):2000;711-722
66. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 50(8):2001;1844-1850
67. Hallsten K., Yki-Jarvinen H., Peltoniemi P., Oikonen V., Takala T., Kemppainen J., et al. Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. Obes Res. 11(2):2003;257-265
68. Bergman R.N. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res. 52:1997;359-385
69. Kitamura T., Kitamura Y., Kuroda S., Hino Y., Ando M., Kotani K., et al. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol. 19(9):1999;6286-6296
70. Deng X., Cagen L.M., Wilcox H.G., Park E.A., Raghow R., Elam M.B. Regulation of the rat SREBP-1c promoter in primary rat hepatocytes. Biochem Biophys Res Commun. 290(1):2002;256-262
71. Wanless I.R., Bargman J.M., Oreopoulos D.G., Vas S.I. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol. 2(2):1989;69-74
72. Mofrad P.S., Sanyal A.J. The relationship between metabolic functions and liver histology in nonalcoholic steatohepatitis before and after treatment [abstract]. Hepatology. October 19, 2003
73. Charlton M., Sreekumar R., Rasmussen D., Lindor K., Nair K.S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 35(4):2002;898-904
74. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 27(1):1998;128-133
75. Berson A., DeBeco V., Letteron P., Robin M.A., Moreau C., El Kahwaji J., et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 114(4):1998;764-774
76. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., Robertson G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 105(8):2000;1067-1075
77. Rao M.S., Reddy J.K. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis. 21(1):2001;43-55
78. Diehl A.M. Cytokine regulation of liver injury and repair. Immunol Rev. 174:2000;160-171
79. Chavin K.D., Yang S., Lin H.Z., Chatham J., Chacko V.P., Hoek J.B., et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 274(9):1999;5692-5700
80. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 6(9):2000;998-1003
81. Hague M. Nonalcoholic steatohepatitis (NASH) is associated with hepatocyte mitochondrial DNA depletion [abstract]. Hepatology. Oct 10:2002;403A
82. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94(9):1999;2467-2474
83. Chalasani N., Gorski J.C., Asghar M.S., Asghar A., Foresman B., Hall S.D., et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 37(3):2003;544-550
84. Tierney D.J., Haas A.L., Koop D.R. Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme. Arch Biochem Biophys. 293(1):1992;9-16
85. Woodcroft K.J., Novak R.F. Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chem Biol Interact. 107(1-2):1997;75-91
86. De Waziers I., Garlatti M., Bouguet J., Beaune P.H., Barouki R. Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line. Mol Pharmacol. 47(3):1995;474-479
87. Woodcroft K.J., Hafner M.S., Novak R.F. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology. 35(2):2002;263-273
88. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 293(5535):2001;1673-1677
89. Hashimoto T., Fujita T., Usuda N., Cook W., Qi C., Peters J.M., et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem. 274(27):1999;19228-19236
90. Hashimoto T., Cook W.S., Qi C., Yeldandi A.V., Reddy J.K., Rao M.S. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem. 275(37):2000;28918-28928
91. Ip E., Farrell G.C., Robertson G., Hall P., Kirsch R., Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 38(1):2003;123-132
92. Senti M., Tomas M., Fito M., Weinbrenner T., Covas M.I., Sala J., et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab. 88(11):2003;5422-5426
93. Ford E.S., Mokdad A.H., Giles W.H., Brown D.W. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes. 52(9):2003;2346-2352
94. Clement S., Krause U., Desmedt F., Tanti J.F., Behrends J., Pesesse X., et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature. 409(6816):2001;92-97
95. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw E.B. III, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 292(5522):2001;1728-1731
96. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 283(5407):1999;1544- 1548
97. Withers D.J., Gutierrez J.S., Towery H., Burks D.J., Ren J.M., Previs S., et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391(6670):1998;900-904
98. Kadowaki T., Tamemoto H., Tobe K., Terauchi Y., Ueki K., Kaburagi Y., et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 and identification of insulin receptor substrate-2. Diabet Med. 13(9 Suppl 6):1996;S103-S108
99. Katz E.B., Stenbit A.E., Hatton K., DePinho R., Charron M.J. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature. 377(6545):1995;151-155
100. Fruman D.A., Mauvais-Jarvis F., Pollard D.A., Yballe C.M., Brazil D., Bronson R.T., et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet. 26(3):2000;379-382